Janssen Pharmaceutica Nv

Vanderbilt University

María Luz Martín-Martín

Susana Conde-Ceide

Michiel Luc Maria Van Gool

Gregor James MacDonald

José Manuel Bartolomé-Nebreda

Óscar Delgado-González

Sergio-Alvar Alonso-de Diego

Michiel Luc Van Gool

Andrés Avelino Trabanco-Suárez

José Ignacio Andrés-Gil

Gary John Tresadern

Greta Constantia Peter Vanhoof

Joaquin Pastor-Fernández

Joaquin Pastor-Fernandez

Greta Constantia Vanhoof

Gregor James Macdonald

Jose Manuel Bartolome-Nebreda

Oscar Delgado-Gonzalez

Craig William Lindsley

P Jeffrey Conn

Shaun R Stauffer

Carrie K Jones

Carina Leys

Johan Erwin Edmond Weerts

Han Min Tong

Stijn Wuyts

Kelly Ann Swinney

Andres Avelino Trabanco-Suarez

Sergio-Alvar Alonso-De Diego

Michiel Van Gool

Johan Erwin Weerts

José Ignacio ANDRÉS-Gil

ÓScar Delgado-GONZÁLEZ

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula I as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ('mGluR2'). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ('mGluR2'). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

6,7-dihydropyrazolo[1,5-&#x3b1;]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor sub-type 2 ('mGluR2') of Formula I:  The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such com-pounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ('mGluR2'). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

[object Object]

Substituted 6,7-dihydropyrazolo[1,5-a] pyrazines as negative allosteric modulators of mGlUR2 receptors

In one aspect, the invention relates to imidazopyrimidin-5(6H)-one analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Substituted imidazopyrimidin-5(6H)-ones as allosteric modulators of MGLUR5 receptors

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases

The present invention relates to novel imidazo[1,2-]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors

Growing community of inventors

Toledo, Spain

María Luz Martín-Martín